LegoChem Biosciences announced that the company has entered into a research licensing agreement with Takeda Pharmaceuticals Company Limited to evaluate next-generation antibody drug conjugate (ADC) candidates. Through this agreement, Takeda will have access to LCB’s proprietary ADC technology, ConjuAll™. ConjuAll™ is LCB’s proprietary next-generation ADC technology platform. Utilizing a site-specific bio-conjugation method and a stable beta-glucuronide linker, ConjuAll™ enables the design of homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells. Under the terms of the agreement, the companies will focus on evaluating novel ADC candidates. Takeda will have an exclusive option to license global rights for the project results. Takeda signed the research licensing agreements with LCB through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc.